Sandbox GGC7
From Proteopedia
(Difference between revisions)
Line 15: | Line 15: | ||
== Disease == | == Disease == | ||
- | + | A mutation of Glu 111 in the active site will render the enzyme inactive or a mutation at Pro 286 will slow down the enzymatic activity. A low functioning or inactive insulin degrading enzyme will allow the buildup of both insulin and amyloid beta-proteins. | |
- | + | ||
- | + | For insulin, if it is allowed to build up, insulin resistance can occur and contribute to the development of type II diabetes. A mutation at Asp 34 will cause Hyperproinsulinemia <ref>doi.org/10.1210/en.135.2.610</ref>, a disease where the body secretes insulin before it has been fully processed (proinsulin) and so does not function properly. | |
- | + | Several different mutations at birth or a young age can contribute to the onset of neonatal diabetes or type I diabetes. The locations are: Asp 24, Arg 32, Ser 32, Gly 43, Val 47, Cys 48, Cys 89, Cys 90, Tyr 96 and Cys 108. | |
- | + | ||
- | + | The buildup of amyloid beta-proteins in the brain has been determined to cause the onset of Alzheimer’s disease <ref>DOI 10.1074/jbc.M900068200</ref>. The onset of Alzheimer’s can also be contributed to the mutation of Ile 714. | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | == Relevance == | ||
- | == Structural highlights == | ||
- | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes. | ||
</StructureSection> | </StructureSection> |
Revision as of 03:22, 16 November 2020
Insulin Protease (Insulin Degrading Enzyme)
|
References
- ↑ Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005 May;26(2):19-39. PMID:16278749
- ↑ Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006 Oct 19;443(7113):870-4. Epub 2006 Oct 11. PMID:17051221 doi:10.1038/nature05143
- ↑ Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem. 2009 May 22;284(21):14177-88. Epub 2009 Mar 25. PMID:19321446 doi:10.1074/jbc.M900068200
- ↑ Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem. 2009 May 22;284(21):14177-88. Epub 2009 Mar 25. PMID:19321446 doi:10.1074/jbc.M900068200
- ↑ doi.org/10.1210/en.135.2.610
- ↑ Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem. 2009 May 22;284(21):14177-88. Epub 2009 Mar 25. PMID:19321446 doi:10.1074/jbc.M900068200